2025 · 2nd Quarter (Apr 1 - June 30)

CSL BEHRING LLC

Filed by THE NICKLES GROUP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: THE NICKLES GROUP, LLC
Client: CSL BEHRING LLC
Filing UUID: e4831267-243e-483c-b707-0716c034a01f
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. H.R. 1, One Big Beautiful Bill Act. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Literal federal measure citations: H.R. 1476, S. 694, H.R. 1

HCR · Health Issues

Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing. Issue regarding plasma-based therapies.

TAX · Taxation/Internal Revenue Code

H.R. 1, One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes.

Literal federal measure citations: H.R. 1

TRD · Trade (domestic/foreign)

Issues related to tariffs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.